Pierre Fabre and Scorpion Therapeutics Initiate Phase I/II Trial of EGFR Inhibitor PFL-241/STX-241 in NSCLC
核心洞察
Pierre Fabre and Scorpion Therapeutics (搜索) have commenced a Phase I/II clinical trial for PFL-241/STX-241 (搜索), a fourth-generation EGFR (搜索) inhibitor.
The trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of PFL-241/STX-241 (搜索) in advanced NSCLC (搜索) patients.
PFL-241/STX-241 (搜索) targets EGFR (搜索) Exon 19 or 21 mutations with the co-occurring C797S mutation, a resistance mechanism to 3rd generation EGFR inhibitors.
Pierre Fabre Laboratories (搜索) and Scorpion Therapeutics (搜索) have announced the dosing of the first patient in a Phase I/II clinical trial evaluating PFL-241/STX-241 (搜索) for the treatment of locally advanced or metastatic non-small cell lung cancer (搜索) (NSCLC (搜索)) harboring EGFR (搜索) Exon 19 or 21 mutations with the co-occurring C797S mutation. This mutation is a known resistance mechanism to third-generation EGFR inhibitors. PFL-241/STX-241 is a highly selective, orally bioavailable tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR).
The Phase I/II trial is an open-label, multi-center study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical efficacy of PFL-241/STX-241 (搜索) as a monotherapy. The trial includes dose-escalation, dose-optimization, and dose-expansion phases.
Significance of EGFR Mutations in NSCLC
NSCLC (搜索) is the most prevalent type of lung cancer, and EGFR (搜索) mutations are significant drivers of the disease, occurring in up to 38% of tumors, depending on geographical location. The development of resistance to existing EGFR inhibitors, particularly through the C797S mutation, represents a critical unmet need in this patient population.
Expert Commentary
"We are eager to begin the clinical evaluation of PFL-241/STX-241 (搜索), our mutant-selective 4th generation EGFR (搜索) inhibitor, a molecule with differentiated properties that we believe has the potential to become a best-in-class therapeutic option for patients developing resistance to current targeted therapy," said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories (搜索). "The initiation of this clinical trial highlights our team's engagement and execution in strong partnership with Scorpion Therapeutics (搜索), and we look forward to demonstrating how patients could potentially benefit from this targeted therapy."
Trial Design and Objectives
The primary objectives of the Phase I/II trial are to determine the recommended Phase 2 dose (RP2D) and to assess the safety and tolerability of PFL-241/STX-241 (搜索). Secondary objectives include evaluating the PK and PD of the drug, as well as assessing preliminary clinical efficacy, including objective response rate (ORR), duration of response (DoR), and progression-free survival (PFS).